A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain

NCT ID: NCT00643383

Last Updated: 2012-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

277 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multi-center placebo controlled, double-blind, trial comparing the analgesic efficacy and safety of Acetram Contramid® BID versus placebo for the treatment of acute low back pain in patients between 18 and 80 yrs of age.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type ACTIVE_COMPARATOR

Combination drug (Acetaminophen + Tramadol)

Intervention Type DRUG

2

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Combination drug (Acetaminophen + Tramadol)

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females in generally good health aged 18-80 years with moderate to severe acute low back pain.
* Current acute low back pain episode within 48h prior to study entry.
* Pain must be moderate to severe following incident

Exclusion Criteria

* Chronic low back pain
* Ongoing or history of alcohol or drug abuse
* Body Mass Index greater 39
* Treatment within the last 3 weeks with monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds; neuroleptics; selective serotonin reuptake inhibitors
* Known history or symptoms suspicious for cancer
* Significant renal or liver disease
* Spinal surgery within 1 year of study entry.
* Subjects who are pregnant or lactating.
* Subjects with unstable medical disease.
* Subjects who have received treatment with an investigational product/device with 30 days prior to study entry.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Labopharm Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Montgomery, Alabama, United States

Site Status

Centennial, Colorado, United States

Site Status

Hialeah, Florida, United States

Site Status

Largo, Florida, United States

Site Status

New Port Richey, Florida, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Waterloo, Iowa, United States

Site Status

Baton Rouge, Louisiana, United States

Site Status

Brockton, Massachusetts, United States

Site Status

Minneapolis, Minnesota, United States

Site Status

Oklahoma City, Oklahoma, United States

Site Status

Rapid City, South Dakota, United States

Site Status

Crossville, Tennessee, United States

Site Status

Bryan, Texas, United States

Site Status

Dallas, Texas, United States

Site Status

Houston, Texas, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Bathurst, New Brunswick, Canada

Site Status

Mount Pearl, Newfoundland and Labrador, Canada

Site Status

Greater Sudbury, Ontario, Canada

Site Status

Newmarket, Ontario, Canada

Site Status

Newmarket, Ontario, Canada

Site Status

Sarnia, Ontario, Canada

Site Status

Toronto, Ontario, Canada

Site Status

Toronto, Ontario, Canada

Site Status

Cowansville, Quebec, Canada

Site Status

Drummondville, Quebec, Canada

Site Status

Gatineau, Quebec, Canada

Site Status

Granby, Quebec, Canada

Site Status

Mirabel, Quebec, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Pointe-Claire, Quebec, Canada

Site Status

Québec, Quebec, Canada

Site Status

Québec, Quebec, Canada

Site Status

Sherbrooke, Quebec, Canada

Site Status

Trois-Rivières, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Lasko B, Levitt RJ, Rainsford KD, Bouchard S, Rozova A, Robertson S. Extended-release tramadol/paracetamol in moderate-to-severe pain: a randomized, placebo-controlled study in patients with acute low back pain. Curr Med Res Opin. 2012 May;28(5):847-57. doi: 10.1185/03007995.2012.681035. Epub 2012 Apr 25.

Reference Type DERIVED
PMID: 22458917 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCT00643383

Identifier Type: REGISTRY

Identifier Source: secondary_id

06CCL3-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.